Celmatix Names Mark Adams as Chief Information Officer

Seasoned executive with deep experience in genomics, cloud
computing, and data analytics to lead efforts to scale informatics
systems

NEW YORK–(BUSINESS WIRE)–Celmatix, a personalized medicine company focused on fertility and
women’s health, today announced it has named Mark Adams, PhD, as its
first Chief Information Officer. In this position, Dr. Adams will play a
critical role on the leadership team, scaling the company’s
bioinformatics and data analytics operations to support both the
upcoming commercial launch of its genetic test and ongoing growth of the
company’s flagship SaaS platform, Polaris.

Dr. Adams is a pioneer in the genomics space, having led some of the
earliest commercial bioinformatics efforts to explore and use genomic
data and information while at companies such as Variagenics and Incyte.
While at Variagenics, he worked to build the company’s first informatics
pipeline, supporting high-throughput SNP genomics. He joins Celmatix
from Good Start Genetics, a leading carrier screening company, where he
served as Chief Information Officer. Prior, he was with Bridgewater
Associates, Ltd., where he developed unique data warehousing and machine
learning approaches to support the world’s largest hedge fund. He was
previously with Booz Allen Hamilton, where he built a leading biomedical
informatics consulting practice focused on clients in the commercial,
government, and nonprofit markets.

“Dr. Adams’s unique background in both bioinformatics and data analytics
made him uniquely qualified for this important role at Celmatix,”
explained Celmatix founder and CEO Dr. Piraye Yurttas Beim. She
continued, “His rich background in the development and deployment of
large-scale software in the bioinformatics community, as well as his
expertise building communities comprised of academic, industry, and
government partners to address healthcare issues are invaluable for
Celmatix in our next phase of growth. We’re thrilled to have his
experience and enthusiasm on our executive team.”

“I am very excited to join Celmatix, and be able to contribute to its
mission of enabling more effective and efficient treatments for
infertility,” Dr. Adams commented. “I have always been drawn to
mission-driven organizations, and I believe that I have found one here.
Working with the committed, talented, and creative community here at
Celmatix will be both fulfilling and fun.”

Dr. Adams received his undergraduate degree from Oberlin College and his
Ph.D. from Baylor College of Medicine. He currently lives in Connecticut
with his wife and two teenage girls.

About Celmatix
Celmatix is a personalized medicine company
that uses big data and predictive analytics to help individuals who are
struggling to have a baby make informed decisions. Founded in 2009 and
based in New York City, Celmatix is disrupting the way women approach
their lifelong fertility journey by empowering them through science and
technology. The company’s flagship product, Polaris, is in use at top
fertility clinics across the country and is the world’s first analytics
platform for optimizing fertility. Celmatix also has an active research
and development program dedicated to decoding the genetic basis of
fertility potential. For more information, visit www.celmatix.com.

Contacts

for Celmatix
Britta Franson, 310-591-7207
britta@brewpr.com